IGF1R has been reported in multiple studies as a key mediator of bypass-resistance to HER2 inhibition;20–22 the top ranking of IGF1R thus validates the capacity of our screening approach to uncover bona fide regulators of tumor cell responsiveness to lapatinib. Here, ERBB2 is linked to neoplasm.